Clinical trials: GvHD
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Chronic Postoperative Pain
Data Collection for Prediction of Postoperative Chronic Pain for a Software
Postoperative Persistent Pain (PPP) is reported with a high incidence in adults 11.5-47%. This high incidence effects quality of life of patients causes social-economical problems and arises medico-legal issues.
- Trial name
- NCT02190682
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 733 people
- Sponsor
- Istanbul University
Acute Lymphoblastic Leukemia
Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International
To evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD).
- Trial name
- ALL SCT BFM (NCT00861679)
- Testing
- Transplantation with Stem Cells from Umbilical Cord
- Where
- Israel
- Volunteers
- 552 people
- Sponsor
- Hadassah Medical Organization
Graft Versus Host Disease
Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease
RATIONALE: Fludarabine may be an effective treatment for graft-versus-host disease caused by bone marrow transplantation. PURPOSE: Phase I/II trial to study the effectiveness of fludarabine in treating patients who have chronic…
- Trial name
- NCT00004194
- Testing
- fludarabine phosphate
- Sponsor
- Jonsson Comprehensive Cancer Center
AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
A significant number of patients with hematologic malignancies need a hematopoietic stem cell transplant (HSCT) to be cured. Only about 50% of these patients have a fully matched donor, the remaining patients will require an HSCT…
- Conditions
- AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Mixed Phenotype Acute Leukemia, NHL - Non-Hodgkin's Lymphoma
- Trial name
- T-allo10 (NCT03198234)
- Testing
- T-allo10
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roncarolo, Maria Grazia, MD
Sickle Cell Disease, Graft Versus Host Disease
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving…
- Trial name
- NCT02867800
- Testing
- Diphenhydramine, Acetaminophen, Methylprednisolone
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Monica Bhatia
Hematologic Diseases, Acute-graft-versus-host Disease
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell transplantation (HSCT) for acute and…
- Conditions
- Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia, Non-Hodgkin Lymphoma (NHL)
- Trial name
- NCT01220297
- Testing
- Sirolimus, Mycophenolate mofetil (MMF), Carmustine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Transplant-Related Disorder
Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model
To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of adult patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset…
- Trial name
- NCT05600855
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Vs Host Disease
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when…
- Trial name
- ABA3 (NCT04380740)
- Testing
- Abatacept
- Where
- 15 sites in United States
- Volunteers
- 160 people
- Sponsor
- Boston Children's Hospital
EBV-T/NK LPD
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of…
- Trial name
- NCT07029958
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Children's Hospital
Graft-Versus-Host Disease
Analysis of the Clinical and Histological Correlation of Oral Graft-Versus-Host-Disease (GVHD)
Introduction: Graft-versus-host-disease (GVHD) is the major cause of morbidity and mortality in patients submitted to the Bone Marrow Transplantation (BMT).
- Trial name
- ORALGVHD (NCT00898885)
- Testing
- oral biopsy
- Volunteers
- 41 people
- Sponsor
- University of Sao Paulo
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder
The purpose of this study is to evaluate the feasibility and acceptability of two different modalities of therapist-guided Internet-delivered behaviour therapy (IBT) for children and adolescents (7-17 years) with Tourette's…
- Trial name
- NCT02864589
- Testing
- Internet-delivered habit reversal training, Internet-delivered exposure and response prevention
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- Karolinska Institutet